News

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) shares plunged 67% to $4.87 after the company announced that its Phase 3 LUGANO trial evaluating DURAVYU in wet age-related macular degeneration failed to meet its primary best-corrected visual acuity endpoint.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) shares finished the session up 18% at $1.65 after the company confirmed that the FDA granted conditional acceptance of CIFBEZY as the proprietary name for ibezapolstat.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced that its Phase 3 LUCIDITY trial for avexitide in post-bariatric hypoglycemia achieved its primary FDA-agreed endpoint, with the GLP-1 receptor antagonist delivering a 55% reduction in Level 2/3 hypoglycemic events compared to placebo.

Apollomics Inc. (NASDAQ: APLM) announced that CEO Chen Hung-Wen acquired about $7.45 million in Class A common stock through a private placement at $12 and $15 per share.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) shares finished the session up 25% at $4.99 after the company finalized its acquisition of Azora Therapeutics, pivoting its strategic priority toward AT177, a colon-targeted oral AhR agonist for ulcerative colitis.

Home Depot (NYSE:HD) delivered second quarter fiscal 2026 results that cleared Wall Street's bar on both earnings and revenue, reinforcing the retailer's narrative of steady execution inside a housing market that has yet to thaw. The results signal that the world's largest home improvement …

USA Rare Earth (NASDAQ:USAR), a Stillwater, Oklahoma based company building an integrated rare earth and permanent magnetSupplychain in the United States, is trading lower in pre-market activity, extending declines following last week's second-quarter report. The company reported an adjusted net loss of $0.15 per …